All In Biotech

Drug Trial Radar · NCT03525119

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue

Last checked: Nov 19, 2026Latest source record: Aug 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

900

Actual

Start

May 16, 2018

Primary completion

Oct 3, 2018

Study completion Jul 9, 2019

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the immunogenicity and safety of the concomitant administration of TDV (subcutaneous \[SC\] injection) and of hepatitis A virus (HAV) vaccine (intramuscular \[IM\] injection) in healthy participants aged 18 to 60 years living in country(ies) non-endemic for both dengue and hepatitis.

Conditions

  • Healthy Volunteers

Interventions

  • TDVBiological

    TDV SC injection

  • HAV VaccineBiological

    HAV Vaccine IM injection.

  • TDV PlaceboBiological

    Placebo-matching (normal saline (0.9% NaCl) SC injection.

  • HAV Vaccine PlaceboBiological

    Placebo-matching (normal saline (0.9% NaCl) IM injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30Time frame: One month post first vaccination (Day 30)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Synexus - Wales

    Cardiff, United Kingdom

  • Synexus - Scotland

    Glasgow, United Kingdom

  • North East Clinical Research Centre, Hexham General Hospital

    Hexham, United Kingdom

  • Synexus - Manchester

    Manchester, United Kingdom

  • Synexus - Thames Valley

    Reading, United Kingdom

  • North Tees Clinical Research Centre, Middlefield Centre, University Hospital of North Tees

    Stockton-on-Tees, United Kingdom

  • Synexus - Midlands

    Edgbaston, Birmingham, United Kingdom

  • Synexus - Lancashire

    Chorley, Lancashire, United Kingdom

  • Synexus - Merseyside

    Waterloo, Liverpool, United Kingdom

  • Royal Hallamshire Hospital

    Sheffield, Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.